**ALKEM LABORATORIES LTD.**
**Regd. Office :** ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.
• Phone: +91-22-3982 9999 • Fax: 022-2495 2955
• Email: contact@alkem.com • Website: www.alkemlabs.com
• CIN: L00305MH1973PLC174201

8th November, 2026

To,

| | |
|---|---|
| **The Corporate Relationship Department**<br>**BSE Limited**<br>Phiroze Jeejeebhoy Towers,<br>Dalal Street,<br>Mumbai 400 001.<br>***Scrip Code: 539523*** | **National Stock Exchange of India Limited**<br>Exchange Plaza,<br>Bandra Kurla Complex,<br>Bandra East,<br>Mumbai 400 051.<br>***Scrip Symbol: ALKEM*** |

**Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("SEBI LODR Regulations") - Intimation of incorporation of subsidiary in the form of Joint Venture.**

Dear Sir/Madam,

This is in furtherance to our earlier intimations dated 12th August, 2025 and 13th February, 2026 with regard to Shareholders' Agreement for incorporation of a subsidiary of the Company in the form of a Joint Venture in the Kingdom of Saudi Arabia (JV).

Pursuant to Regulation 30 of the SEBI LODR Regulations, we wish to inform you that subsidiary of the Company in the form of a Joint Venture in the name of 'Alkem Pharma Company**',** Limited Liability Company has been incorporated in the Kingdom of Saudi Arabia on 8th November, 2026.

Particulars of the disclosure required under SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, have been provided in Annexure – I.

Kindly take the same on your records.

Sincerely,
For **Alkem Laboratories Limited**

MANISH NARANG
Digitally signed by MANISH NARANG
Date: 2026.11.08 18:27:23 +05'30'

**Manish Narang**
**President – Legal, Company Secretary & Compliance Officer**

ALKEM LABORATORIES LTD.
**Regd. Office :** ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.
• Phone: +91-22-3982 9999 • Fax: 022-2495 2955
• Email: contact@alkem.com • Website: www.alkemlabs.com
• CIN: L00305MH1973PLC174201

## Annexure – I

| Sr. No. | Particulars | Details |
|---|---|---|
| a. | Name of target entity, details in brief such as size, turnover etc. | **Name of Joint Venture**: 'Alkem Pharma Company', Limited Liability Company ("Alkem Pharma")<br><br>**Capital**: 7,500,000.0 SAR divided into 75,000.0 shares of 100 SAR each<br><br>**Turnover**: Not Applicable |
| b. | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length" | The acquisition does not fall under related party transaction.<br><br>None of the promoter / promoter group / group companies have any interest in the entity. |
| c. | Industry to which the entity being acquired belongs | Pharmaceuticals and Nutraceuticals |
| d. | Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | The investment in the Subsidiary is a strategic investment undertaken by the Company with the objective of expanding the Company's business and market reach to the Kingdom of Saudi Arabia. |
| e. | Brief details of any governmental or regulatory approvals required for the acquisition | Not Applicable |
| f. | Indicative time period for completion of the acquisition | Not Applicable |
| g. | Consideration – whether cash consideration or share swap or any other form and details of the same | Cash consideration |
| h. | Cost of acquisition and/or the price at which the shares are acquired | Subscription of 38,250 Shares of 100 SAR each amounting to 3,825,000.00 SAR. |
| i. | Percentage of shareholding / control acquired and / or number of shares acquired | 51% of the total share capital of the Subsidiary. |
| j. | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) | **Brief Background:** The Subsidiary is incorporated as a limited liability company and will be involved in the manufacture, import, marketing and distribution of pharmaceutical and/or nutraceutical products within the Kingdom of Saudi Arabia. |